Cardiovascular effects of the thiazolidinediones
- 26 September 2005
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 22 (2) , 88-97
- https://doi.org/10.1002/dmrr.596
Abstract
Thiazolidinediones, used for the treatment of diabetes mellitus type 2, modulate gene expression by binding to nuclear transcription factor, peroxisome proliferator‐activated receptor‐gamma. Peroxisome proliferator–activated receptor‐gamma is expressed in several tissues, therefore, thiazolidinediones have biological effects on multiple organ systems. Here, we describe evidence that thiazolidinediones have beneficial effects on the cardiovascular system independent of their antidiabetic effect. Studies in animals have clearly shown that thiazolidinediones decrease blood pressure, left ventricular hypertrophy, development of atherosclerotic lesions, and protect myocardium from ischemia/reperfusion injury. Although relatively few studies in humans have been reported, the preponderance of available evidence suggests a beneficial effect of thiazolidinediones. Thus, by modulating gene expression, thiazolidinediones may provide a novel method for the prevention and treatment of cardiovascular diseases. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 104 references indexed in Scilit:
- Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Attenuates Myocardial Ischemia/Reperfusion Injury in a Rat ModelLaboratory Investigation, 2003
- Rosiglitazone Reduces the Accelerated Neointima Formation After Arterial Injury in a Mouse Injury Model of Type 2 DiabetesCirculation, 2003
- Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning studyAmerican Heart Journal, 2003
- Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic PatientsCirculation, 2003
- Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery DiseaseCirculation, 2003
- Aortic Stiffness Is an Independent Predictor of Primary Coronary Events in Hypertensive PatientsHypertension, 2002
- Management of Co-Existing Diabetes Mellitus and DyslipidemiaAmerican Journal of Cardiovascular Drugs, 2002
- Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator–activated receptor γJournal of Clinical Investigation, 2000
- Insulin Resistance, Hyperinsulinemia, and Blood PressureHypertension, 1997
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990